Pacira BioSciences (PCRX) Total Debt Growth (3y) (2013 - 2026)
Pacira BioSciences (PCRX) Total Debt Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Debt Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | -2.21% |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | -7.03% |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.29% |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 63.29% |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | - |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 1,183.78% |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | -7.76% |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | - |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | -14.15% |
| 10 | Pacira BioSciences | 1.05 Bn | 846.97 Mn | 140.96 Mn | 35.32% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 35.32% |
| Dec 31, 2025 | -19.86% |
| Sep 30, 2025 | 6.73% |
| Jun 30, 2025 | -5.18% |
| Mar 31, 2025 | -5.57% |
| Dec 31, 2024 | 4.70% |
| Sep 30, 2024 | 25.58% |
| Jun 30, 2024 | -10.62% |
| Mar 31, 2024 | -7.22% |
| Dec 31, 2021 | 1,165.94% |
| Sep 30, 2021 | 675.46% |
| Jun 30, 2021 | 675.12% |
| Mar 31, 2021 | 674.04% |
| Dec 31, 2018 | -85.19% |
| Sep 30, 2018 | -85.29% |
| Jun 30, 2018 | -85.30% |
| Mar 31, 2018 | -85.36% |
| Dec 31, 2017 | -85.35% |
| Sep 30, 2017 | -85.36% |
| Jun 30, 2017 | -85.33% |